Home › Lupus Nephritis › California
Lupus Nephritis clinical trials in California
15 studies for Lupus Nephritis are looking for participants at sites in California.
Cities in California
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Ronald Reagan UCLA Medical Center, Los Angeles
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Oct 1, 2026 · NCT05268289VIBRANT: VIB4920 for Active Lupus Nephritis
- University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La Jolla
- UCLA Medical Center: Division of Rheumatology, Los Angeles
- of California, Irvine School of Medicine Division of Rheumatology, Orange
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05201469Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
- University of California San Francisco - Zuckerberg San Francisco General, San Francisco
RecruitingPhase 1
Ages 18 to 60 · All sexes · Updated Sep 14, 2026 · NCT06975787The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
- University of California, San Francisco, San Francisco
RecruitingPhase 2
Ages 8 to 20 · All sexes · Updated Sep 14, 2026 · NCT05538208A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
- Wallace Rheumatic Studies Center, Beverly Hills
- Kaiser Permanente Fontana, Fontana
- Providence Medical Foundation, Fullerton
- and 2 more
RecruitingPhase 2
Ages 12 to 70 · All sexes · Updated Sep 14, 2026 · NCT07570862A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, San Francisco
- Research Site, Stanford
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 10, 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Loma Linda University health, Loma Linda
- UCSF Benioff Childrens Hospital, San Francisco
RecruitingPhase 2
Ages 5 to 17 · All sexes · Updated Sep 3, 2026 · NCT05039619A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Aug 28, 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of California Irvine, Orange
- UC Davis Health, Sacramento
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Aug 26, 2026 · NCT06121297PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Purushotham & Akther Kotha MD, Inc., La Mesa
- Valerius Medical Group & Research Center of Greater Long Beach, Inc., Los Alamitos
RecruitingPhase 4
Ages 18 to 75 · All sexes · Updated Aug 3, 2026 · NCT07611214A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
- Nkarta Investigational Site, Tustin
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 4, 2026 · NCT06557265A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- and 2 more
RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978Lupus Landmark Study: A Prospective Registry and Biorepository
- Wallace Rheumatic Studies Center, Beverly Hills
- UCLA, Los Angeles
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Apr 15, 2026 · NCT05934149Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
- Lucile Packard Children's Hospital, Palo Alto
RecruitingPhase 1/2
Ages 1 to 30 · All sexes · Updated Jul 17, 2023 · NCT05508009From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.